Biopharma | Ophthalmology Innovation Source

Anido Guides Aerie’s Push To Be A “Very Big Player” In Glaucoma

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 009″] Vicente Anido, Jr., PhD’s career has taken him through large companies and private start-ups. He’s taken life science companies public on two occasions, and he’s seen nearly every perspective of the ophthalmology industry. Today, Anido expects big things for Aerie Pharmaceuticals, a clinical-stage pharmaceutical company with two promising treatments for…

Lindstrom: Ophthalmologists Facing Both Opportunity & Pressure

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 005″] Richard L. Lindstrom, MD, a long-time supporter of ophthalmology start-ups, looks ahead at the challenges facing physicians and investors as they work to meet the growing demand for ophthalmic treatment in an evolving healthcare industry. Podcast Guest Richard Lindstrom, MD Dr Richard L Lindstrom, Founder and attending surgeon at Minnesota…

Cunningham: Strong Signs Ahead For Ophthalmology Innovation

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 004″] OIS Co-Chair, Emmett T. Cunningham, Jr., MD, recounts the origin of the Ophthalmology Innovation Summits and his time at the formative Eyetech Pharmaceuticals, while sharing in earnest his hopes for ophthalmology as an industry. Podcast Guest Emmett T. Cunningham Jr., MD, PhD, MPH Dr. Cunningham joined Clarus Ventures with 20+…

Link Says Versant’s Eyes Will Be On Ophthalmology

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 002″] Bill Link explains why ophthalmology will continue to be a pillar for Versant’s new fund. He also talks about the impact of industry consolidation, the Sunshine Act, and he offers helpful advice to entrepreneurs and physicians looking to turn inspiration into innovation. Podcast Guest William J. Link, PhD Bill was…

pSivida

Paul Ashton talks about the innovation within pSivida and its early stage work on proteins. pSivida has developed 3 of the 4 sustained delivery systems for the vitreous and retina that have been approved either in the US or the EU Presenter: Paul Ashton Dr. Ashton has over 25 years experience in drug delivery. He…

Panoptes Pharma

Franz Obermayr gives a short overview of Panoptes Pharma founded only last year, covering only one of their developments: C0C01 for local treatment in ophthalmology. Presenter: Franz Obermayr, PhD Dr. Franz Obermayr is Co-Founder and serves as CEO of Panoptes. Before that he was Head of Clinical Development at Nabriva, where he led the clinical efforts…

Ocular Therapeutix

Amar Sawhney gives us an update on what’s going on in Ocular Therapeutix, showing us an in depth look at their product pipeline and what we can look forward to. Presenter: Amar Sawhney, PhD Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since served as President and CEO and was elected Chairman of the…

Eleven Biotherapeutics

Presenter: Abbie C. Celniker, PhD Dr. Celniker brings more than 20 years of proven protein therapeutic expertise to Eleven Biotherapeutics. Prior to joining Eleven, Abbie was CEO of Taligen Therapeutics, which was acquired by Alexion Pharmaceuticals. View Full Profile

Mimetogen

Presenter: Garth Cumberlidge Garth Cumberlidge has served as the Company’s President, CEO and member of the Board of Directors since September 2005. Dr. Cumberlidge has over 25 years’ experience in the research products, diagnostics and healthcare industries. View Full Profile

Next Generation Ocular Drug Delivery Platforms

The human eye measures approximately one inch in diameter, but traversing that blink-of-an-eye distance to achieve safe, effective and stable delivery of ophthalmology drugs via minimally or non-invasive medical devices to treat major eye diseases has taken more than 40 years to accomplish. Is the wait for a Holy Grail product in ophthalmology medical technology…

2013 Ophthalmic Market – “Year in Review”

Emmett T. Cunningham Jr. MD PhD MPH, Partner at Clarus Ventures and Summit Chairman, delivers an overview of some ophthalmic highlights from 2013. Sharing key accomplishments from many device and pharma companies, Emmett continues to expand on the present landscape with promising data to show that the ophthalmology market is stable despite the decrease in…

PanOptica Offers a “Do it Yourself” Treatment for Neovascular AMD

PanOptica – Paul Chaney, President & CEO for PanOptica, expands upon averting intravitreal injections with a topically, self-administered eye drop to treat Neovascular AMD. Striving to decrease the burden of injections and injection related risks, Paul shares the company’s unique discovery that led to their many successes. Presenter: Paul Chaney Paul G. Chaney is Co-Founder,…